Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aleksas Matvekas"'
Autor:
Bo Wen, Shaomeng Wang, Duxin Sun, Miao He, Paul D. Kirchhoff, Weiguo Xiang, Chong Qin, Xin Han, Donna McEachern, Lu Wang, Hoda Metwally, Aleksas Matvekas, Lijie Zhao, Yu Wang, Bukeyan Miao
Publikováno v:
J Med Chem
We report herein the discovery of exceptionally potent and orally bioavailable PROTAC AR degraders with ARD-2585 being the most promising compound. ARD-2585 achieves DC(50) values of ≤0.1 nM in the VCaP cell line with AR gene amplification and in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3122d4af987b9531939410c88a01d073
https://doi.org/10.1021/acs.jmedchem.1c00900
https://doi.org/10.1021/acs.jmedchem.1c00900
Autor:
Xin Han, Aleksas Matvekas, Bukeyan Miao, Weiguo Xiang, Bo Wen, Lijie Zhao, Chong Qin, Yu Wang, Lu Wang, Hoda Metwally, Donna McEachern, Shaomeng Wang, Duxin Sun
Publikováno v:
J Med Chem
Proteolysis targeting chimera (PROTAC) small-molecule degraders have emerged as a promising new type of therapeutic agents, but the design of PROTAC degraders with excellent oral pharmacokinetics is a major challenge. In this study, we present our st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b5ec7f1a36d9c56757326ebe0059a4
https://doi.org/10.1021/acs.jmedchem.1c00882
https://doi.org/10.1021/acs.jmedchem.1c00882
Autor:
Morgan J Homan, Holly Roberts, Aleksas Matvekas, Manjunath P. Pai, Carl Koschmann, Bernard L. Marini, Andrea Franson, Karthik Ravi, Cai Liu, Miao He
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Panobinostat, an orally bioavailable pan-HDAC inhibitor, has demonstrated potent activity in multiple malignancies, including pediatric brain tumors such as DIPG, with increased activity against H3K27M mutant cell lines. Given limited eviden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a4829cc94df0c692c462a79c7daa30f
https://europepmc.org/articles/PMC8896403/
https://europepmc.org/articles/PMC8896403/
Publikováno v:
Antimicrob Agents Chemother
Background: This risk of vancomycin (VAN)-associated acute kidney injury (AKI) may be altered with combination regimens. The specific AKI risk when VAN is combined with imipenem-cilastatin/relebactam (IMP-C/REL) or piperacillin/tazobactam (TZP) has n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b5217182783f02bc581e301eb62083
https://doi.org/10.1128/aac.02141-20
https://doi.org/10.1128/aac.02141-20
Autor:
Nicholas O. Stevers, Miao Chia Lo, Chang-Ching Lin, Jeanne A. Stuckey, Samantha L. Tinsley, Aleksas Matvekas, Duxin Sun, Jennifer L. Meagher, Rebecca Moody, Inkyung Jung
Publikováno v:
The Journal of biological chemistry. 293(6)
The transcription factor BCL11A has recently been reported to be a driving force in triple-negative breast cancer (TNBC), contributing to the maintenance of a chemoresistant breast cancer stem cell (BCSC) population. Although BCL11A was shown to supp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b72a6479fc9414cc0c53cd9f2324cce
https://pubmed.ncbi.nlm.nih.gov/29263092
https://pubmed.ncbi.nlm.nih.gov/29263092